US › Healthcare

Bright Minds Biosciences Inc (DRUG)

US · Healthcare · Biotechnology

$61.55+4.13%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-2.5M

EPS

$-0.17

EPS estimate

$-1.39

EPS came in at -0.17 against a street estimate of -1.39 — a beat of 87.8%.

Key statistics

Market cap

$619.9M

Forward P/E

0.0

P/B

2.87

Book value

$22.60

EPS (TTM)

$-2.06

52-week high

$123.75

52-week low

$44.25

50-day MA

$74.30

200-day MA

$77.97

Beta

-0.11

Analyst view

Analysts rate Bright Minds Biosciences Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $169.88.

Shareholding

Insiders

11.94%

Institutions

94.87%

Largest institutional holders

Fund	Stake
HHG PLC	13.02%
Cormorant Asset Management, LLC	10.74%
BlackRock Inc	6.30%
Vivo Capital, LLC	5.65%
BRAIDWELL LP	5.47%
Vestal Point Capital LP	4.99%
Driehaus Capital Management LLC	4.38%
Perceptive Advisors LLC	3.83%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bright Minds Biosciences Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.